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Abstract 
Progressive aging of the population and prolongation of life expectancy have led to the rising prevalence of heart failure (HF). Despite 
the improvements in medical therapy, the mortality rate of this condition has remained unacceptably high, becoming the primary cause of 
death in the elderly population. Almost half of patients with signs and symptoms of HF are found to have a nearly normal ejection fraction, 
which delineates a distinct clinical syndrome, known as HF with preserved ejection fraction (HF-PEF). While early research focused on the 
importance of diastolic dysfunction, more recent studies reported the pathophysiological complexity of the disease with multiple cardiovas-
cular abnormalities contributing to its development and progression. HF-PEF is a challenging major health problem with yet no solution as 
there is no evidence-based treatment which improves clinical outcomes. This review summarizes the state of current knowledge on diagnosis, 
prognosis and treatment of HF-PEF, with particular insights on the pathological characteristics in the elderly population. 
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1  Introduction  
The elderly population (age > 65) has been steeply in-
creasing in the last 3 decades.[1] Given the advances in ther-
apy, the future elderly population can be expected to keep 
on rising and contribute more actively to society. Heart fail-
ure (HF) is a progressive disorder in a continuum superim-
posed on the aging process, which leads to disability and 
ultimate death. Progressive changes during aging and the 
cardiovascular disease evolution contribute to increase the 
heart failure burden in the elderly, Figure 1.[2] Almost half of 
the patients with symptomatic heart failure (HF) will be 
found to have a preserved ejection fraction (PEF); these will 
more likely be elderly and women, with a history of hyper-
tension, obesity and other co-morbidities.  
HF can be defined as an abnormality of cardiac structure 
or function leading to failure of the heart to deliver oxygen 
at a rate commensurate with the requirements of the me-
tabolizing tissues, despite normal filling pressures (or only 
at the expense of increased filling pressures).[3] It is a com-
mon syndrome, prevalent in aging populations worldwide. 
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Approximately 1%–2% of the adult population in developed 
countries has HF, with the prevalence rising to ≥ 10% 
among persons70 years of age or older.[4] HF is the final 
common pathway of several diseases with an increasing 
prevalence with population aging and improved treatment.  
 
Figure 1.  Heart failure: relationship between disease pro-
gression and superimposed ageing. CAD: coronary artery disease; 
COPD: chronic obstructive pulmonary disease; HF-PEF: Heart 
failure with preserved ejection fraction; MI: myocardial infarction. 
2  Diagnosis of heart failure 
According to the two most recent guidelines on HF pub-
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lished from the European Society of Cardiology (ESC) in 
2012[3] and from the American College of Cardiology 
Foundation/American Heart Association (ACCF/AHA) in 
2013,[5] HF can be divided in two clinically distinctive syn-
dromes by widely used measures of pump dysfunction. 
Typically, this is left ventricular ejection fraction (LVEF) 
which is easily and often measured using echocardiography. 
Many major trials have enrolled patients with low LVEF ≤ 
35%–40% (so-called heart failure with reduced ejection 
fraction or HF-REF). However, up to half of all patients 
with HF present with an ejection function within the normal 
range (so-called heart failure with preserved ejection frac-
tion (HF-PEF)).[6] HF-PEF has been variably classified due 
to the differing LVEF cut-off criteria and the challenging 
diagnostic criteria. Table 1 shows the main differences in 
definition, classification and diagnosis in HF between the 
European and the American Guidelines. Of major concern 
is how the ACCF/AHA staging system for HF focuses more 
on the progression and worsening of the condition over time 
and recognizes the need for earlier identification of the con-
tributing underlying conditions. The diagnosis of HF usu-
ally occurs in symptomatic patients after a period of dysp-
noea or edema.[7] However, HF is usually preceded by other 
conditions, such as coronary artery disease, diabetes, 
hypertension or valve disease.[8,9] HF is often the final, and 
fatal, stage of disease progression. This classification system 
moves forward from one stage to the next based on the pro-
gression of the disease, with the following proposed stages: 
(1) Stage A patients at high risk for developing clinical HF 
(i.e., those with hypertension, diabetes, dyslipidemia, and so 
on), but without detectable structural heart disease; (2) Stage 
B patients with detectable structural heart disease (i.e., left 
ventricular hypertrophy (LVH), left ventricular (LV) dys-
function), but no clinical signs or symptoms of HF; (3) 
Stage C patients with current or past clinical HF; and (4) 
Stage D patients with end-stage refractory HF. 
Table 1.  Major differences in HF definition, classification and HF-PEF diagnosis between the ESC and ACCF/AHA Guidelines.  
 
2012 ESC Guidelines for the diagnosis and treatment of acute 
and chronic heart failure 
2013 ACCF/AHA Guideline for the management of heart 
failure 
HF definition 
Abnormality of cardiac structure or function leading to failure of 
the heart to deliver oxygen at a rate commensurate with the re-
quirements of the metabolizing tissues, despite normal filling 
pressures (or only at the expense of increased filling pressures). 
Complex clinical syndrome that results from any structural or 
functional imparment of ventricular filling or ejection of 
blood. 
 
HF classification 
HF-REF 
Symptoms 
Signs 
Reduced LVEF (LVEF < 45%) 
HF-PEF 
Symptoms 
Signs 
Normal or mildly reduced LVEF and LV not dilated 
Relevant structural and/or functional heart disease 
 
 
 
Stage A 
At high risk for HF but without structural heart disease or 
symptoms 
Stage B 
Structural heart disease but without signs or symptoms 
Stage C 
Structural heart disease with prior or current symptoms 
of HF 
HF-REF (LVEF ≤ 40%) 
HF-PEF 
Stage D 
Refractory HF 
HF-PEF diagnosis 
Requires 4 conditions to be satisfied 
Typical symptoms of HF 
Typical signs of HF 
Preserved LVEF and LV not dilated 
EF ≥ 45% 
LVEDVi < 97 mL/m2 
LVEDDi < 29 mm2 
Relevant structural heart disease and/or diastolic dysfunction 
LAVi > 34 mL/m2 
LVMi > 115 g/m2 (M) 
LVMi > 95 g/m2 (F) 
E/E’ ≥ 8 
E’ average < 9 cm/s 
Stage C HF 
Known structural heart disease 
Typical Signs and Symptoms 
Preserved LVEF 
a. LVEF ≥ 50% 
HF-PEF 
b. LVEF 41-50% 
Borderline HF-PEF 
 
 
 
 
 
F: female; HF-REF: heart failure with preserved ejection fraction; LAVi: left atrial volume indexed; LVEDDi: left ventricular end diastolic diameter indexed; 
LVEDVi: left ventricular end diastolic volume indexed;  LVEF: left ventricular ejection fraction; LVMi: left ventricular mass indexed; M: male. 
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Only the latter two stages qualify for the traditional clin-
ical diagnosis of HF for diagnostic or coding purposes. 
Moreover, the classification recognizes that there are estab-
lished risk factors and structural prerequisites for the devel-
opment of HF and that therapeutic interventions performed 
even before the appearance of LV dysfunction or symptoms 
can reduce the morbidity and mortality of HF. The system is 
complementary to the New York Heart Association (NYHA) 
functional classification, which primarily gauges the sever-
ity of symptoms in patients who are in Stage C or D. 
On the other hand, the European Society of Cardiology 
adopted a complementary classification that underlines the 
major difference between the two clinical HF syndromes: 
HF-REF and HF-PEF. These syndromes differ in terms of 
pathophysiology, epidemiology, diagnosis and prognosis. 
While HF-REF is the best understood type of HF in terms of 
pathophysiology and treatment, HF-PEF seems to have a 
different epidemiological and etiological profile.[10,11] Pa-
tients with HF-PEF are older, more often female and more 
obese compared with those with HF-REF. They are less 
likely to have coronary heart disease and more likely to 
have a history of hypertension and atrial fibrillation.[12] In 
the past, HF-PEF was described as diastolic HF, and efforts 
were made to differentiate a cause for diastolic dysfunction, 
and a subsequent target for therapy.[13] While it is sometimes 
possible to demonstrate abnormalities in diastolic dysfunc-
tion, a specific therapy has thus far remained elusive.[14] It is 
now recognized, however, that due to effective therapies 
and remodelling, patients with borderline or normal LVEF 
may have primarily systolic dysfunction.[15] 
3  HF in the elderly  
In HF, as in many other cardiovascular diseases, impor-
tant sexual dimorphisms exist in disease epidemiology and 
clinical outcomes. While in HF-REF, most studies show 
that men outnumber women, probably partly because the 
leading cause of this disease is coronary artery disease. In 
HF-PEF, females are approximately two times more likely 
than men to develop heart failure.[16,17] Many of the cardio-
vascular alterations seen in HF-PEF are noted to greater 
extent in women compared with men.[18] For example, 
women demonstrate more concentric left ventricular re-
modelling and less ventricular dilatation in response to arte-
rial hypertension;[19] ventricular and arterial stiffness in-
creases with age in both sexes, but the increase is more 
dramatic in women.[20] And lastly, obesity influences LV 
geometry substantially more in women than in men- adipose 
mass is greater in women than men in any weight category, 
and obese women have greater LV mass than obese men.[21] 
Recently, age–sex interactions have also been observed in 
the manner in which LV function changes across the life-
span, wherein systolic and diastolic function and functional 
reserve become more compromised in women as compared 
with men in the postmenopausal years, despite similar or 
enhanced function in women during youth.[22] Finally, re-
garding outcome, it has been demonstrated that women with 
HF have a lower risk of death in both HF-REF and HF-PEF 
when compared to HF men. This better prognosis is more 
marked in non-ischemic HF.[23] 
4  Left ventricular geometry 
Left ventricular geometry is often altered in HF patients 
and there are clear differences in cardiac structure and func-
tion comparing patients with HF-REF and HF-PEF. Firstly, 
in HF-REF there is eccentric remodelling, where the LV is 
dilated and an adequate stroke volume is maintained at a 
lower LVEF. This eccentric remodelling is typically medi-
ated through ischemic events.[24] In contrast, in patients pre-
senting with HF-PEF concentric remodelling, the LV 
end-diastolic volume is not increased relative to the stroke 
volume, and maintenance of cardiac output is achieved at 
higher LVEF.[25,26] Secondly, in HF-REF, LV systolic elas-
tance (the relationship between volume and pressure) is 
reduced, whereby arterial elastance is elevated, resulting in 
impaired ventricular–vascular coupling. In contrast, both 
LV and arterial elastance are increased in HF-PEF, so that 
the coupling between them is preserved. In fact, the pres-
ence of a normal LVEF indicates that the coupling of the 
LV and arterial system is nearly optimal to convert the en-
ergy of contraction into stroke work. Thus, arterial vaso-
dilatation improves LV systolic performance in HF-REF, 
but not in HF-PEF.[27−29] Many therapies are proven to im-
prove outcome in HF-REF, including ACE inhibition,[30,31] 
β-blockade,[32−34] aldosterone antagonists,[35,36] and oth-
ers.[37−39] many of which are associated with reverse remod-
elling. However, none have been demonstrated to be effec-
tive in patients with HF-PEF.[40−42] In retrospect, probably 
this is due to the lack of LV dilation in patients with 
HF-PEF, reflecting different pathological processes.[43] 
5  Diagnosis 
The diagnosis of HF-PEF is more difficult than the di-
agnosis of HF-REF because it is largely one of exclu-
sion.[44,45] Detecting the syndrome is typically done by 
clinical assessment, echocardiography and supportive evi-
dence from biomarkers (B type natriuretic peptide and its 
variants). Because of the non-specific symptoms and signs 
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of HF of any type, there has been some doubt about the na-
ture of patients enrolled in the main HF-PEF clinical tri-
als.[46,47] The higher frequency of obesity and chronic lung 
disease among patients with HF-PEF has even led to the 
suggestion that these patients may just be elderly, over-
weight women who do not even suffer from a real HF.[48-51] 
HF-PEF diagnosis requires objective documentation of a 
cardiac dysfunction, both systolic and diastolic,[52] as shown 
in Table 1. 
Echocardiography is the main tool used in HF diagnosis; 
it is used to define etiology and to assess the extent of ec-
centric remodelling. It has also been widely used to assess 
the therapeutic impact of various pharmacological interven-
tions upon remodelling.[53] Although echocardiography is 
exemplary in the setting of HF-REF, there are some limita-
tions in detecting subtle myocardial dysfunction and for 
quantifying small changes in LVEF. This is especially true 
in women with small volumes and hypertrophic hearts. In 
terms of diastolic dysfunction, echocardiography is used to 
evaluate the dynamics of left ventricular filling, mitral an-
nular motion, and left atrial size. An elevated E: E’ ratio and 
increased left atrial size are, until now, the best diastolic 
measures used to assist with recognizing HF-PEF in com-
mon practice.  Moreover, evaluation of diastolic function 
provides important prognostic information in a wide variety 
of patients. Using a combination of Doppler measurements, 
four grades of diastolic function have been defined based 
upon mitral blood flow (Figure 2). In patients with HF, the 
stage of diastolic dysfunction is a stronger predictor of mor-
tality than EF.[54] The most severe grades of diastolic dys-
function indicate a 4-fold increase in the risk of death in 
patients with heart failure and coronary artery disease.[55] 
Similarly, it was been shown that the presence of a normal 
filling pattern in community subjects with symptoms of HF, 
indicates a very good prognosis, while in contrast, an ab-
normal filling pattern and progressively worse grades of 
diastolic dysfunction indicate patients with a progressively 
increased risk of subsequent mortality.[56,57] Furthermore, the 
introduction of tissue Doppler indices, in particular the ratio 
of early mitral flow/early annulus velocity, can be used to 
indicate poor prognosis in a variety of patients.[58] Tissue 
Doppler parameters even predict mortality in a general pop-
ulation of patients, most of whom were free of apparent 
systolic and diastolic dysfunction by conventional echocar-
diographic methods.[59] Recently, the progressive LV filling 
abnormalities in outpatients with preserved LV systolic 
function has been proven to be a strong, independent pre-
dictor of all-cause mortality.[60] 
 
Figure 2.  The stages of diastolic dysfunction recognized by changes in left ventricle filling dynamics. (A) Pulsed-wave Doppler of 
mitral inflow and (B) Pulsed-wave tissue Doppler of mitral annulus in progressive stages. Diastolic filling grades: classification of diastolic 
filling and representative mitral inflow pulsed wave Doppler and mitral annulus pulsed wave tissue Doppler signals; E/A: ratio of passive 
early to active late mitral filling velocities; Deceleration time: time from peak to baseline of the mitral E velocity; Ea/Aa: ratio of the early 
mitral annular velocity to the late annular velocity; Amitral: duration of filling of the late filling velocity of the mitral inflow; ARpulmonary: dura-
tion of atrial reversal component of the pulmonary venous inflow. Statement: this figure was adapted from Whalley GA, Wasywich CA, 
Walsh HJ, Doughty RN. The role of echocardiography in the contemporary management of heart failure. Expert Rev Cardiovasc Ther 2005; 
3(1): 51−70, which was authorized by the publisher. 
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6  Prognosis 
The differentiation of HF-PEF and HF-REF is important, 
since we know that patients with HF-PEF have a better 
prognosis than those with HF-REF, although it is still very 
high in both groups. [61] Many studies have enrolled patients 
with HF-PEF (for example, DIG-PEF,[62] CHARM-Pre-
served,[63] and I-PRESERVE[64]) providing an interesting 
comparative group. Campbell, et al.[65] have compared out-
comes in HF-PEF with patients of similar age, sex distribu-
tion and co-morbidity that were enrolled in trials of hyper-
tension, diabetes mellitus, angina pectoris and atrial fibrilla-
tion, and demonstrated that patients in the HF-PEF trials 
were at higher risk of death and at strikingly higher risk of 
HF hospitalizations. No data about underlying pathology, 
including diastolic dysfunction can be made, but it is con-
ceivable that patients with HF-PEF may have more diastolic 
dysfunction than similar patients without HF-PEF.[66] This 
diastolic dysfunction occurs in the presence of LV hyper-
trophy often, but interestingly, the median N-terminal pro– 
B-type natriuretic peptide concentration was much higher in 
the I-PRESERVE trial than the LIFE study, which enrolled 
hypertensive patients, despite the greater LV mass in LIFE 
suggesting that LV hypertrophy and presumable underlying 
cardiac function may be important.[67] Similarly, while LV 
mass in CHARM-Preserved was analogous to that in LIFE, 
median N-terminal pro-B-type natriuretic peptide was twice 
that of LIFE.[68]  A better understanding of why N-terminal 
pro–B-type natriuretic peptide is elevated to a greater extent 
in some patients with HF-PEF than in patients with similar 
clinical presentation is clearly important, given the prognos-
tic importance of this peptide in HF-PEF.[69] 
7  Characterization of LV dysfunction in 
HF-PEF  
As has been previously demonstrated in the MAGGIC 
study,[70] the implications of missing data can be substantial. 
In this case, previous studies with up to 70% missing data 
had erroneously reported that HF-PEF had similar mortality 
as HF-REF. In fact, the main bias was the missing LVEF 
among some groups of patients, such as the elderly popula-
tion. As patients with HF-PEF are older, if some are ex-
cluded due to the lack of LVEF measurements, there is a 
higher probability of systemic selection bias when compar-
ing HF-REF and HF-PEF patients. The impact of this bias 
has been recently evaluated.[71] Compared to patients with 
known LVEF, patients missing a EF measurement (HF-mEF) 
were older, had a greater prevalence of chronic obstructive 
pulmonary disease (COPD), previous stroke, and were 
smokers. This group is associated with poor short and long 
term survival, similar to the HF-REF population.[71] In addi-
tion, even if we examine the assessment of diastolic dys-
function in HF-PEF, the data are variable. Assignment of a 
specific pattern may not be possible, and patients have been 
excluded from prior studies on this basis. A systematic 
analysis performed by Narayanan, et al.[72] indicated that 
even with expert acquisition and interpretation, assignment 
of LV filling patterns is not possible in up to one-third of 
patients. A metric that is feasible in all patients, is load in-
dependent, yields a single continuous variable number, is 
quick, reliable, and automated would be desirable, but has 
thus far been elusive.[73] Therefore, the missing data in both 
systolic and diastolic disfunction is of major concern, espe-
cially in the elderly population which suffers the most from 
this lack of evaluation and resulting poor outcome, probably 
due to erroneous diagnosis and treatment. 
8  Treatment and implications in the elderly 
population 
No treatment has yet been demonstrated to reduce mor-
bidity and mortality in patients with HF-PEF, as described 
in HF management guidelines (Table 2). Diuretics are used 
to control sodium and water retention and relieve breath-
lessness and edema, as in HF-REF. Adequate treatment of 
hypertension and myocardial ischemia is also considered to 
be important, as is control of the ventricular rate in patients 
with atrial fibrillation.[74] Moreover, randomized trials on 
elderly HF patients are lacking, although HF-PEF is noted 
to greater extent in the aging population. However, the use 
of pharmacological and non-pharmacological therapies is 
currently recommended by the HF guidelines in both 
non-elderly and elderly patients, with specific cautions in 
the latter. The main reasons leading to poor outcome in this 
population are the suboptimal application of therapy[75] and 
the lack of mortality benefits in the HF-PEF group, with its 
higher prevalence especially in the older patients. Sub-op-
timal therapy is due to co-morbidities and their difficult 
management, reduced compliance, increased susceptibility 
to renal dysfunction, impairment of sodium and water ex-
cretion, and therapy aggravated postural hypotension and 
bradyarrhythmias. However, these conditions should not 
discourage therapy, but be kept in consideration for tailoring 
treatment.  
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Table 2.  Major differences in HF-PEF treatment recommendations between the ESC and ACCF/AHA Guidelines. 
 
2012 ESC Guidelines for the diagnosis and treatment  
of acute and chronic heart failure 
2013 ACCF/AHA Guideline for the management  
of heart failure 
Class 1 
Blood pressure control (LOE B) 
Diuretics for symptoms relief (LOE C) 
Class 2a 
Coronary revascularization in CAD (LOE C) 
a. Symptomatic or 
b. Myocardial Ischaemia 
AF management (LOE C) 
If hypertension use of ACE inibitors and beta blockers (LOE C) 
Use of PUFA in NYHA 2-4, unless controindicated (LOE B) 
Class 2b 
No treatment has yet been shown to reduce morbidity and mortality 
Use of ARBs (LOE C) 
AF: atrial fibrillation; ARBs: angiotensinreceptor blockers; CAD: coronary artery disease; HF-PEF: Heart failure with preserved ejection fraction; LOE: level 
of evidence; PUFA: omega-3 polyunsatured fatty acid. 
 
9  Conclusions 
HF-PEF is a complex and common disease, with a high 
and constantly increasing prevalence. Detecting the syn-
drome is still difficult because of its non-specific nature of 
symptoms and signs, especially in the elderly population. 
While HF-PEF patients are at higher risk of death and hos-
pitalizations than similar age and co-morbidity profile pa-
tients, treatment is still empirical and no therapy has yet 
shown significant impact on mortality. This is why we be-
lieve there is urgent need of increased awareness and clini-
cal research in the field. 
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